Trump Lied About Not Getting Any Calls Against Marijuana Rescheduling, GOP Senator Suggests

Trump marijuana rescheduling executive order lit up Washington like a neon OPEN sign flickering over a late-night diner—inviting everyone in, daring someone to start a fight. At the signing, the president said the phone never rang with opposition. Not once. That’s a bold claim in a town built on ringing phones and selective memory. Within hours, a Republican senator, Ted Budd of North Carolina, said he’d called the president directly days earlier to argue against federal marijuana rescheduling—and that he knew other lawmakers had weighed in, too. Politics is the art of the story you choose to tell. One version: a leader riding a wave of public support for cannabis reform. Another: a White House kitchen where the chef insists the critics loved the meal, even as they send plates back to the pass with red pens and gritted teeth.

Here’s what we know. Public sentiment favors change on marijuana policy reform. The president leaned into that, pitching rescheduling as grounded in science, empathy, and a little common sense—less reefer madness, more modern medicine. Budd, meanwhile, led a push among Senate Republicans to keep cannabis right where it is, warning against loosening federal controls while others in the House echoed the resistance. This is the friction point: a noisy Capitol, a quieter country, and a policy question dressed like a culture war. You can feel the split-screen—polling that screams “move” and a conservative bloc that hears “risk,” not reform. If you’ve spent time in the weeds of federal drug law, you know the soundtrack already: security on one channel, freedom and economic logic on the other.

Rescheduling from Schedule I to Schedule III won’t legalize marijuana nationwide, but it changes the business math overnight. Schedule III could lift the IRS’s 280E handcuffs, letting compliant cannabis companies finally deduct ordinary expenses—payroll, rent, the lights left on at closing time. Research barriers, too, begin to crumble, making it easier to run trials, publish data, and get past the bureaucratic choke points that trapped cannabis in the last century. The market impact? Expect pressure on margins, consolidation plays, and a more professionalized industry footprint. Banking and capital, perennially jammed, may start to thaw if Congress catches the scent of an easy bipartisan win. For a deeper dive into that pivot point, see GOP Senator Says Marijuana Banking Bill Remains Stalled—But Trump’s Rescheduling Order Could Spur Congress To Act. Big picture: Schedule III is a policy nudge with outsized market shockwaves—less revolution, more recalibration, but no less consequential for operators who’ve been taxed and boxed out like pariahs.

Not everyone’s on board. Several Republican attorneys general have framed the move as a public-safety gamble, warning that federal rescheduling could complicate enforcement and send the wrong message. If you want the statehouse flavor of that argument, start with GOP State Attorneys General Push Back On Trump’s Marijuana Move, Saying It Could Harm ‘The Safety Of Our Citizens’. Their brief is part jurisprudence, part political theater: federal posture shifts while states juggle their own legalization and enforcement frameworks. Meanwhile, the Sunshine State previews the next act. The legal skirmish over whether voters even get to decide marijuana policy underscores the stakes—see Florida Attorney General Asks Supreme Court To Review 2026 Marijuana Legalization Ballot Initiative. Rescheduling doesn’t flip a switch on interstate commerce, and it won’t erase the patchwork of state laws, but it does drag the federal government closer to where many voters—and markets—have already migrated.

When the president points to suffering and medicine, he’s reading a page most of the country knows by heart. Families looking for relief aren’t debating DEA schedules; they’re asking what works. That’s the subtext behind stories like Trump Touts Medical Marijuana As ‘Substitute For Addictive’ Opioids—But Says He Has No Interest In Using It Himself. Of course, Washington will keep arguing over who called whom and what was said. That’s the business model. But out beyond the Beltway, in the dispensaries and labs and grow rooms, the shift to Schedule III could finally align tax policy, research access, and reality. And if you’re following the fast-evolving cannabis landscape and want to explore compliant, premium options for your own regimen, step into our shop and look around: https://thcaorder.com/shop/